Cargando…

A fully human anti-CD47 blocking antibody with therapeutic potential for cancer

CD47/SIRPα interaction serves as an immune checkpoint for macrophage-mediated phagocytosis. Mouse anti-CD47 blocking antibodies had demonstrated potent efficacy in the treatment of both leukemic and solid tumors in preclinical experimentations, and therefore had moved forward rapidly into clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Dadi, Sun, Qiang, Chen, Ang, Fan, Jiangfeng, Yang, Xiaopeng, Xu, Lei, Du, Peng, Qiu, Weiyi, Zhang, Weicai, Wang, Shuang, Sun, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347751/ https://www.ncbi.nlm.nih.gov/pubmed/27863402 http://dx.doi.org/10.18632/oncotarget.13349

Ejemplares similares

CD47-Blocking Antibodies and Atherosclerosis
por: Ryan, John J.
Publicado: (2016)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis
por: Kojima, Yoko, et al.
Publicado: (2016)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody
por: Qiu, Weiyi, et al.
Publicado: (2015)

CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy
por: Cao, Anthony, et al.
Publicado: (2022)

The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
por: Shi, Rui, et al.
Publicado: (2020)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
por: Lin, Fangzhen, et al.
Publicado: (2021)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer
por: Shi, Chenyang, et al.
Publicado: (2022)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells
por: Liu, Liang, et al.
Publicado: (2017)

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
por: Wu, Hao, et al.
Publicado: (2021)

CD47 as a promising therapeutic target in oncology
por: Zhao, Hai, et al.
Publicado: (2022)

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
por: Kaur, Sukhbir, et al.
Publicado: (2016)

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
por: Liu, Jie, et al.
Publicado: (2015)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Anti-CD47 antibody eliminates bone tumors in rats
por: Fang, Shiqiang, et al.
Publicado: (2019)

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer
por: Zhang, Xuyao, et al.
Publicado: (2019)

Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
por: Yang, Hongcheng, et al.
Publicado: (2019)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety
por: Li, Yulu, et al.
Publicado: (2023)

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes
por: Mathias, Melissa D., et al.
Publicado: (2017)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
por: Qiu, Weiyi, et al.
Publicado: (2019)

CD47 on artificial structures
por: Schütz, Christian
Publicado: (2015)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
por: Hatterer, Eric, et al.
Publicado: (2020)

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells
por: Thaker, Youg R., et al.
Publicado: (2022)

Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission
por: Canepa, Gaspar E., et al.
Publicado: (2018)

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer
por: Yoshida, Kazumichi, et al.
Publicado: (2015)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

CD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis
por: Weiskopf, Kipp, et al.
Publicado: (2015)

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2017)

Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy
por: Zhu, Huaiyang, et al.
Publicado: (2017)

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5mcdhten1njll5s5nkdlp1flh6